February 2026 Research Update

What treatment studies added this month

This month, human studies focused less on brand-new medicines and more on how existing approaches might be used in real life, in specific situations. In type 1 Gaucher disease, registry data suggested that some clinically stable people who stretched enzyme infusions to every 3 to 4 weeks had similar Gaucher-related outcomes to those staying on the usual every-2-week schedule. Separate registry data in pregnancy added reassurance that many imiglucerase-treated pregnancies resulted in live births without a clear safety signal attributed to imiglucerase, while still reflecting that complications can occur during pregnancy for many reasons. [1] [2]

A small pediatric case series in type 2 Gaucher disease described long-term follow-up of ambroxol (a medicine sometimes studied as a "chaperone" to help enzyme function) used together with enzyme replacement therapy. One child had age-appropriate development reported into early childhood with sustained biomarker improvement, while the other showed biochemical improvement but continued developmental delays, highlighting that responses may differ between individuals and may depend on the specific GBA1 variants. [3]

Two other pieces of research supported ambroxol-related work without testing patient outcomes in a larger group. One pharmacy study found compounded ambroxol capsules stayed within quality specifications for 6 months under tested storage conditions, which matters mainly for making future small trials feasible. [4]

Early laboratory and animal work explored a different idea: nanoparticles designed to stabilize glucocerebrosidase (the enzyme affected in Gaucher disease). In Gaucher-like mouse and cell models, these nanoparticles increased measured enzyme activity in several organs and were linked with improved motor function in mice, but this is not yet evidence of benefit for people. [5]

What this may mean for patients and families

For people with type 1 Gaucher disease who are already stable on enzyme replacement therapy, the new registry comparison adds evidence that some patients in routine care have done similarly over years after moving to less frequent infusions, at least for the outcomes tracked in the registry. This does not prove the same approach fits everyone, but it helps clarify that infusion frequency is an active research question being studied in real-world settings. [1]

For pregnancy, the registry report provides more real-world outcome data in women treated with imiglucerase during pregnancy, with most reported pregnancies resulting in live births and no stillbirths reported in this dataset. Because this is observational registry information (with some missing data and no untreated comparison), it mainly adds context rather than a definitive answer about how much imiglucerase changes pregnancy risks. [2]

For neuronopathic Gaucher disease, ambroxol plus enzyme replacement therapy was described in only 2 children, with one doing much better than the other in development despite both showing biomarker changes. The main value right now is that it documents what long-term combined treatment looked like in real children, while also underscoring that outcomes can vary and that larger studies would be needed to know how often this pattern occurs. [3]

The nanoparticle study and the capsule stability study are enabling steps rather than care-changing results. The animal and cell findings give an early signal that boosting enzyme stability might be possible in principle, and the capsule study supports consistent preparation for planned small clinical testing, but neither tells us yet whether these approaches will improve symptoms or daily life for patients. [5] [4]

What became clearer about diagnosis this month

Across studies, the consistent message was that diagnostic delay and access remain major issues, and that structured testing pathways can help but still face real-world barriers. A patient and caregiver survey across many countries reported that more than half waited over a year for a diagnosis, often tied to low awareness and weak communication across specialties. In parallel, two programs using dried blood spot testing showed that wider screening is feasible in different settings, but also highlighted practical challenges like sample quality and incomplete follow-up genetic confirmation. [6] [7] [8]

In Sardinia, a standardized approach combining dried blood spot enzyme testing with biomarkers and targeted genetics found 1 confirmed Gaucher case among 196 people tested for suspected lysosomal diseases, while several others had low enzyme activity that was not always genetically confirmed. This illustrates both the potential for stepwise screening to find missed cases and the reality that a low first-line enzyme result does not always equal a confirmed diagnosis without follow-up testing. [7]

In a pilot effort across 8 Sub-Saharan African countries, clinician training plus cross-border dried blood spot testing identified Gaucher diagnoses among referred samples, but also produced a notable number of artefactual results linked to heat and humidity and faced transport and logistics barriers. The study shows that expanding diagnostic capacity is possible, while emphasizing that reliable sample handling and referral pathways are part of the "diagnosis" problem too. [8]

What this may mean for patients and families

The survey data helps put a number on something many families experience: delays in getting Gaucher disease recognized and named, and gaps in being told it is genetic. This matters now because delays can prolong uncertainty and lead to more testing for other conditions before Gaucher is considered, even though the survey cannot prove why any one person had a delay. [6]

The dried blood spot studies add practical evidence that enzyme and biomarker screening can be organized as a pathway, including in regions where specialist testing is hard to access. They also clarify what remains uncertain: screening results can be affected by sample handling, and some people with abnormal screening tests may not get confirmatory genetic testing, which can leave families without a clear final answer. [7] [8]

What the case reports collectively showed

This month, case-based reports reinforced that neuronopathic Gaucher disease type 3 can sometimes first show up as progressive myoclonus epilepsy (recurrent jerks and seizures that can worsen over time), even before more typical Gaucher signs are obvious. Across the published cases reviewed, seizures were often difficult to control, early brain scans could look normal, and changes like brain shrinkage could appear later. Together, these reports strengthen the picture that unexplained progressive myoclonus epilepsy is one situation where metabolic enzyme testing and genetic testing may help reach an underlying diagnosis. [9]

In one new patient description, a 20-year-old man had drug-resistant seizures despite multiple anti-seizure medicines and vagus nerve stimulation, and testing showed very low glucocerebrosidase activity with two GBA1 variants. The authors highlighted that he did not have visceral involvement reported at presentation, which underscores how varied the starting signs can be. [9]

A separate report of a 4-year-old girl with a rare homozygous GBA1 p.Ser276Phe variant described partial improvement in myoclonic jerks with levetiracetam but ongoing neurologic progression over 6 months, including worsening balance and cognitive decline. This case adds to the idea that specific genetic variants may be linked to different patterns of neurologic change, but single cases cannot predict what will happen for another child. [10]

What this may mean for patients and families

These reports mainly add understanding rather than changing care, but they can help families recognize the range of neurologic symptoms that have been reported in neuronopathic Gaucher disease. The larger review within the case report helps clarify a common pattern: progressive myoclonus epilepsy in Gaucher type 3 often begins in childhood and is frequently hard to control with standard seizure treatments. [9]

What remains uncertain is how much any one genetic change predicts an individual course, because the evidence here comes from single patients and a collection of past case reports. Still, the month adds a clearer message that when progressive myoclonus epilepsy is unexplained, confirming or ruling out Gaucher with enzyme and genetic testing can be an important part of finding the cause. [9] [10]

What was found about social media content

A study of TikTok videos across several rare genetic diseases found a consistent gap between visibility and information quality. Videos made by physicians and other medical professionals tended to score higher for quality, while influencer and patient/family videos tended to have more views and engagement but lower quality scores. For Gaucher disease specifically, this study did not find a statistically significant difference in quality by creator type, which may reflect limited numbers or mixed content. [11]

The same analysis found that very few videos cited scientific literature, regardless of who created them. This helps explain why social media can feel informative but still leave important details missing, especially for rare diseases where nuances matter. [11]

What this may mean for patients and families

This study does not evaluate treatments or symptoms directly, but it does add evidence that popular short videos about rare diseases often do not meet the same quality standards as medical sources. For patients and caregivers, the main value is knowing that high engagement does not reliably signal high-quality information, and that references to sources are uncommon. [11]

What remains uncertain is whether lower-quality videos change health decisions, because the study did not measure behaviors or outcomes. Even so, it offers a clearer explanation for why people can receive mixed messages online about Gaucher disease and other genetic conditions. [11]